MCCP
ABBV icon

Mission Creek Capital Partners’s AbbVie ABBV Stock Holding History

Mission Creek Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$887K Sell
17,933
-2,020
-10% -$435K 0.16% 114
2026
Q1 		$1.21M Sell
19,953
-9,539
-32% -$2.12M 0.24% 92
2025
Q4 		$3.45M Sell
29,492
-243
-0.8% -$55.4K 0.7% 36
2025
Q3 		$3.55M Sell
29,735
-273
-0.9% -$55.6K 0.7% 35
2025
Q2 		$2.9M Sell
30,008
-444
-1% -$82.5K 0.64% 38
2025
Q1 		$3.36M Sell
30,452
-52
-0.2% -$10.1K 0.82% 32
2024
Q4 		$2.86M Buy
30,504
+14,422
+90% +$2.65M 0.63% 40
2024
Q3 		$3.18M Sell
16,082
-269
-2% -$50.2K 0.74% 35
2024
Q2 		$2.8M Buy
16,351
+4,173
+34% +$691K 0.71% 37
2024
Q1 		$2.22M Buy
12,178
+637
+6% +$110K 0.58% 48
2023
Q4 		$1.79M Sell
11,541
-82
-0.7% -$12K 0.46% 59
2023
Q3 		$1.73M Sell
11,623
-76
-0.6% -$11.2K 0.58% 51
2023
Q2 		$1.58M Buy
11,699
+1,251
+12% +$183K 0.51% 62
2023
Q1 		$1.67M Buy
10,448
+1,394
+15% +$213K 0.57% 60
2022
Q4 		$1.46M Buy
9,054
+158
+2% +$24.2K 0.52% 67
2022
Q3 		$1.19M Buy
8,896
+156
+2% +$22.4K 0.45% 77
2022
Q2 		$1.34M Sell
8,740
-27
-0.3% -$4.13K 0.45% 82
2022
Q1 		$1.42M Buy
8,767
+234
+3% +$34K 0.38% 90
2021
Q4 		$1.16M Buy
8,533
+92
+1% +$10.9K 0.23% 118
2021
Q3 		$911K Sell
8,441
-895
-10% -$102K 0.17% 134
2021
Q2 		$1.05M Buy
9,336
+1,234
+15% +$139K 0.17% 113
2021
Q1 		$877K Buy
8,102
+36
+0.4% +$3.85K 0.13% 114
2020
Q4 		$864K Buy
8,066
+631
+8% +$60.6K 0.26% 102
2020
Q3 		$651K Buy
7,435
+6
+0.1% +$565 0.26% 108
2020
Q2 		$729K Buy
7,429
+1,196
+19% +$105K 0.38% 70
2020
Q1 		$475K Sell
6,233
-25
-0.4% -$2.13K 0.26% 89
2019
Q4 		$554K Buy
+6,258
New +$520K 0.25% 103

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Mission Creek Capital Partners's ABBV Position: Q2 2026 in Review

Mission Creek Capital Partners reduced its AbbVie (ABBV) stake by 10% in Q2 2026, selling an estimated $435K and leaving 17,933 shares worth $887K. The position accounts for 0.16% of the portfolio, ranked #114.

Mission Creek Capital Partners first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. The position peaked at $3.55M in Q3 2025. 4,227 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Mission Creek Capital Partners held 17,933 shares of AbbVie worth $887K as of Q2 2026.
  • Mission Creek Capital Partners sold 2,020 AbbVie shares in Q2 2026, an estimated $435K.
  • AbbVie made up 0.16% of Mission Creek Capital Partners's portfolio in Q2 2026, its #114 holding.
  • Mission Creek Capital Partners first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • Mission Creek Capital Partners's AbbVie position peaked at $3.55M in Q3 2025.
  • 4,227 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Mission Creek Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.